Moderna (MRNA) said Friday its trial for a trivalent vaccine against norovirus is currently on hold by the US Food and Drug Administration after a single adverse event report of a close of Guillain-Barre syndrome.
Investigation of the adverse event is currently underway, according to the company.
Moderna said it expects the clinical hold will not impact the efficacy readout timeline for the northern hemisphere trial as enrollment has already been completed.
Shares were up nearly 4% in recent trading.
Price: 33.07, Change: +1.15, Percent Change: +3.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.